Organization Overview
Alternative names
efgartigimod (Vyvgart) (2021 NDA)
Leukemia (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 2)
Muscle Weakness (Phase 3)
Myasthenia Gravis (Phase 3)
Myelodysplastic Syndromes (Phase 2)
Nasopharyngeal Carcinoma (Phase 1)
Neoplasms (Phase 1)
Paresis (Phase 3)
Pemphigus (Phase 3)
Polyneuropathies (Phase 2)
Preleukemia (Phase 2)
Purpura, Thrombocytopenic, Idiopathic (Phase 3)
Syndrome (Phase 2)
Thrombocytopenia (Phase 3)